Custodes Futurifor the advancement of humanity

Jonas Salk 1914-1995

Contribution. He developed the first widely used polio vaccine. It used "killed" poliovirus. The virus was inactivated with formaldehyde so that it could not cause disease. But it still prompted the body to make protective antibodies (Science History Institute).

At a glance

ItemDetail
Dates1914-1995
FieldMedicine and public health
Case typePioneer
Discrimination or exclusionNo

Factor coverage

Favorable entries (helped or barrier absent) and adverse entries (barrier or not overcome) by factor. Factor tags are this site's classification.

Barriers faced

FactorsStatement
Economic EducationalAn immigrant family. He was born in New York. By his own account, his mother came from Russia in 1901 with no schooling. He also said that his father designed ladies' neckwear in the garment industry and had only an elementary school education, and that his generation was the first in the family to go to college (Academy of Achievement). Sources differ on whether his father was also an immigrant (Salk Institute) or the son of Jewish immigrants (Science History Institute). None of the sources checked describes the family's income.
Societal Cultural EducationalAdmission quotas. A 2018 essay draws on Charlotte DeCroes Jacobs's biography. It states that unofficial quotas limited Jewish admission to most medical schools. It says Salk was rejected nearly everywhere he applied, and that only New York University offered him a place (The New Atlantis). This is a single secondary account.
Cultural SocietalRejected for research posts. He did his internship at Mount Sinai Hospital. After that, several prestigious university hospitals and research institutes turned him down. The same essay says this was because of a preference for "Ivy League gentiles."
Social CulturalSkepticism of peers. Most virologists, including Albert Sabin, believed that only a live, weakened virus could give lasting immunity. In 1950 the polio typing committee rejected the method changes he proposed. Before the 1954 trial, Sabin argued to the American Medical Association and to Congress that a killed-virus vaccine was neither effective nor safe.
Technological SocietalThe Cutter incident. In April 1955 more than 200,000 children in five Western and Midwestern states got vaccine from Cutter Laboratories. In this vaccine the virus had not been fully inactivated. It caused 40,000 cases of polio. It left 200 children with some paralysis and killed 10 (Journal of the Royal Society of Medicine). Paul Offit's history of the incident clears Salk of blame. It puts the main responsibility on the federal regulator. But the incident fed calls by Sabin and others to stop using his vaccine.

What helped

FactorsStatement
Educational EconomicFree public education. He went to Townsend Harris Hall, a selective public high school in Manhattan, and finished at 15 (The New Atlantis, Science History Institute). He then went to City College of New York and graduated with a science degree in 1933. He entered NYU's medical school at 19.
Social EducationalA mentor. Thomas Francis Jr. trained him at NYU on inactivated influenza vaccines. When other positions turned him down, Salk went back to Francis. In 1942 he joined him at the University of Michigan on a National Research Council fellowship. There, with U.S. Army support, they developed a killed-virus flu vaccine.
Societal EconomicHis own laboratory. In 1947 the University of Pittsburgh made him director of a new Virus Research Laboratory. The National Foundation for Infantile Paralysis gave him a first-year grant of nearly $150,000. He joined its project to type polioviruses. By 1951 that project confirmed three virus types.
EnvironmentalOthers' discoveries. In 1949 Enders, Weller, and Robbins grew poliovirus in tissue culture of non-nerve tissue. This let Salk grow large amounts of all three types in monkey kidney cells.
SocialA team. His Pittsburgh staff included Julius Youngner, Byron Bennett, and L. James Lewis. Three others joined later. Youngner developed ways to grow the virus in monkey kidney cells. He also made a color test to measure antibodies (Boston Globe).
Economic SocietalPublic donations. President Roosevelt announced the National Foundation for Infantile Paralysis in September 1937. It was incorporated on January 3, 1938. It paid for the research and trials with private donations through its March of Dimes campaign. Eddie Cantor coined that name in November 1937. It became the organization's formal name only in 1979 (March of Dimes).
Societal SocialMass participation and an independent evaluation. Volunteers ran the 1954 trial. Francis directed it, not Salk. The 1955 report counted 1,829,916 children in the study areas. This included observed controls who got no injection (University of Michigan School of Public Health). Other accounts give from 1 million to almost 2 million because they count different groups. Jacobs's biography, as summarized by Valiunas (2018), puts those who got the vaccine at over 600,000. In April 1955 the vaccine was reported safe and 80 to 90% effective against paralytic polio.

Not overcome

FactorsStatement
Social SocietalHe was very famous with the public. Even so, he was never elected to the National Academy of Sciences, which admitted Sabin, Francis, Enders, and David Bodian (KQED, The New Atlantis). He never received a Nobel Prize. In the 1960s Sabin's oral live-virus vaccine replaced his in the United States.

Notes

FactorsStatement
SocialCredit and patents. Some colleagues criticized Salk for not crediting the researchers his work built on. Members of his own team said he failed to single them out in his April 12, 1955, announcement speech. A United Press report at the time quoted him crediting six staff members. The printed text was headed "From the Staff of the Virus Research Laboratory." But Youngner confronted Salk about the speech in 1993. Salk did not patent the vaccine. Edward R. Murrow asked him who owned the patent on his television program See It Now. This was on April 12, 1955, the day the trial results were announced (The New Atlantis, Smithsonian Magazine, Slate). He answered, "Well, the people, I would say. There is no patent. Could you patent the sun?" (History of Vaccines). The historian Jane S. Smith found documents in the National Foundation's archives, as reported by Slate. According to them, the Foundation's lawyers had looked at whether the vaccine could be patented. They concluded that it did not meet the novelty requirement (Slate). A History.com account says instead that the lawyers did not pursue a patent in part because of Salk's reluctance (History.com). Smith's book was not opened for this document.

Pattern summary

ElementIn this case
Door-openerFrancis
Knowledge sourceFree public college, NYU, training under Francis
Institutional supportMarch of Dimes, University of Pittsburgh
Built on recent workEnders, Weller, Robbins
Setback overcomeRejections, peer skepticism, Cutter incident
Barrier not overcomeCredit disputes, never elected to the National Academy of Sciences

Sources

  1. Smithsonian Magazine: Jonas Salk
  2. Science History Institute: Salk and Sabin
  3. University of Michigan School of Public Health: 1955 polio vaccine trial announcement
  4. Salk Institute for Biological Studies. About Jonas Salk
  5. Fitzpatrick, M. (2006). Review of The Cutter Incident by Paul Offit. Journal of the Royal Society of Medicine, 99(3), 156
  6. Valiunas, A. (2018). Jonas Salk, the people's scientist. The New Atlantis, Summer/Fall 2018
  7. Brooks, J. (2015, August 17). Jonas Salk: Public hero, professional pariah. KQED
  8. Tan, S. Y., and Ponstein, N. (2019). Jonas Salk (1914-1995): A vaccine against polio. Singapore Medical Journal, 60(1), 9-10
  9. Najera, R. F. (2021, May 6). Vaccine patents and public health. History of Vaccines, College of Physicians of Philadelphia
  10. Julius Youngner, polio vaccine pioneer, obituary. (2017, May 5). Boston Globe
  11. PBS. A Science Odyssey: People and Discoveries: Jonas Salk
  12. March of Dimes. Origin of our name
  13. Palmer, B. (2014, April 14). Jonas Salk: Good at virology, bad at economics. Slate
  14. Klein, C. (2014, October 28, updated 2026, March 6). 8 things you may not know about Jonas Salk and the polio vaccine. History.com
  15. Academy of Achievement. (1991, May 16). Jonas Salk interview and biography
  16. UC San Diego Library, Special Collections and Archives. Salk (Jonas) Papers, 1926-1991 (MSS 0001), finding aid, biography. Online Archive of California
  17. City University of New York. History: Origins and formative years
  18. City University of New York. History: Creation of the modern university
  19. Lengel, E. (2025, December 1). Jonas Salk: A Life (review of Jacobs's biography). Grateful American Foundation

Also relevant: Bell, A., Chetty, R., Jaravel, X., Petkova, N., & Van Reenen, J. (2019). Who becomes an inventor in America? Quarterly Journal of Economics, 134(2), 647-713. All references